MABs
CDC Urges Need for Boosters, COVID-19 Action Plan for Immunocompromised
With monoclonal antibodies lacking efficacy, the CDC urged all people, especially those who are immunocompromised, ...
FEBRUARY 13, 2023
FDA: Sotrovimab Ineffective Against New Omicron Subvariant
The FDA limited the EUA for sotrovimab in parts of the United States, because the authorized dose is unlikely to be ...
MARCH 31, 2022
FDA Limits Use of Monoclonal Antibodies to Treat COVID-19
The FDA revised the EUAs for two monoclonal antibody cocktails for COVID-19, essentially saying the should not be ...
JANUARY 25, 2022
Pharmacists Authorized to Order and Administer COVID-19 Therapeutics Under PREP Act Declaration
An amendment to the PREP Act broadly addresses the pharmacist's role in providing COVID-19 therapeutics, including ...
SEPTEMBER 17, 2021
FDA Limits Use of COVID-19 Monoclonal Antibody Combination to States With Low Rates of Resistance
The FDA has revised its emergency use authorization for the monoclonal antibodies bamlanivimab and etesevimab to ...
SEPTEMBER 3, 2021
FDA Authorizes Baricitinib Alone as COVID-19 Treatment
The FDA revised the emergency use authorization (EUA) for baricitinib to enable its use alone for the treatment of ...
JULY 29, 2021
FDA Authorizes Use of Actemra for COVID-19
The FDA issued an EUA Actemra to treat hospitalized adults and children who are receiving systemic corticosteroids ...
JUNE 28, 2021
FDA Revokes EUA for Bamlanivimab Monotherapy for COVID-19; Still Authorized in Combination
Although the FDA revoked its EUA for bamlanivimab monotherapy, the agency said it could still be given ...
APRIL 21, 2021
Challenges to Uptake of Monoclonal Antibody Therapies for COVID-19: Lessons Learned
Issues identified in the introduction and uptake of monoclonal antibody therapies for COVID-19 offer key insights ...
APRIL 21, 2021